Therefore, exceeding the packaging capacity of AAV vectors and the challenges of efficiently targeting both the liver and kidneys may hinder the progress of genomic medicines in treating PKHD1‐associated ARPKD. Here, PKHD1 is linked to autosomal recessive polycystic kidney disease.